Accéder au contenu
Merck

6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H.

European journal of medicinal chemistry (2018-07-23)
Lei Wang, Jing Tang, Andrew D Huber, Mary C Casey, Karen A Kirby, Daniel J Wilson, Jayakanth Kankanala, Michael A Parniak, Stefan G Sarafianos, Zhengqiang Wang
RÉSUMÉ

Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RNase H) remains an unvalidated drug target. Reported HIV RNase H inhibitors generally lack significant antiviral activity. We report herein the design, synthesis, biochemical and antiviral evaluations of a new 6-biphenylmethyl subtype of the 3-hydroxypyrimidine-2,4-dione (HPD) chemotype. In biochemical assays, analogues of this new subtype potently inhibited RT RNase H in low nanomolar range without inhibiting RT polymerase (pol) or integrase strand transfer (INST) at the highest concentrations tested. In cell-based assays, a few analogues inhibited HIV in low micromolar range without cytotoxicity at concentrations up to 100 μM.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
2,3-Dihydroxypyridine, 95%